Rockwell Medical Agrees to Buy Most of Vantive's Hemodialysis Business for $125 Million

Rockwell Medical said on Tuesday it has agreed to buy the majority of Vantive's hemodialysis business for an aggregate base purchase price of $125 million, a deal the company said would turn it from a US-based concentrates business into a more diversified global supplier. Rockwell's release says the transaction is expected to close in mid-2027, subject to regulatory approvals and other closing conditions, and cautions that it may not be completed on that timeline or at all.

What changes hands

Under the Equity and Asset Purchase Agreement, Rockwell will acquire Vantive's hemodialysis concentrates, hemodialysis machines including the AK-98, water treatment systems, and related consumables and technical services business.

The deal also includes a manufacturing campus in Medolla, Italy, which Rockwell describes as one million square feet. The company said the site currently makes dry concentrate cartridges, hemodialysis machines, related parts and consumables, and water treatment systems.

Vantive's own announcement said its dialyzer portfolio, including the Theranova dialyzer, is not part of the transaction. Vantive's release does not state the price, as the trade publication 24x7 noted; the financial terms come from Rockwell.

How the deal is financed

Rockwell said the $125 million base price, which is subject to customary adjustments, will be financed through two $50 million term loans from Vantive plus a $25 million convertible note issued to Vantive. The seller is therefore financing the base purchase price under these terms.

The note's initial conversion price is set at a 100% premium to the 15-day volume-weighted average price of Rockwell's common stock, as determined under the transaction documents. Vantive may also receive up to $45 million of additional contingent consideration based on specified revenue and EBITDA milestones.

Rockwell said it is withdrawing its previously issued 2026 guidance for net sales, gross margin, adjusted EBITDA and operating cash flow because of expected transaction-related and financing-related expenses.

What the companies say

Rockwell estimates that the combined business could generate annual revenue between $400 million and $450 million. The company said that estimate rests on assumptions including operating performance, exchange rates, market conditions and successful integration, and its risk disclosures note that it is based in part on historical financial information provided by Vantive.

Mark Strobeck, Rockwell's president and CEO, said in the release that the deal has the potential to add product breadth, global distribution, manufacturing and research infrastructure, technical service capabilities and "recurring revenue streams that would take years to build organically."

Vantive framed the sale as a sharpening of its focus on home dialysis and critical care. "This announcement brings Vantive's ambition into sharper focus," CEO Chris Toth said in the company's statement, describing a portfolio centered on care at home and in the intensive care unit. Toth said Vantive is committed to working with Rockwell through the transition to help ensure continuity of care and access to products and services.

Rockwell's risk disclosures list, among other items, its ability to service the term loans, potential dilution from the convertible note and the significantly increased size and complexity of its business after the transaction.